cilostazol has been researched along with Blood Pressure, High in 16 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Cilostazol is useful for the prevention of the recurrence of vascular events in patients with lacunar infarction, and is probably effective in high-risk patients with diabetes and/or hypertension." | 5.13 | Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study. ( Fukuuchi, Y; Gotoh, F; Hirai, S; Itoh, E; Matsuda, T; Nishimaru, K; Ohashi, Y; Otomo, E; Sawada, T; Shinohara, Y; Terashi, A; Tohgi, H; Yamaguchi, T, 2008) |
| " Sex-specific odds ratios of age, diabetes mellitus (DM), hypertension (HTN), coronary artery disease (CAD), cerebral vascular accident (CVA), or using cilostazol for LEA or PRP were explored." | 3.77 | Determinants of lower extremity amputation or revascularization procedure in patients with peripheral artery diseases: a population-based investigation. ( Chen, JJ; Lee, CH; Liau, CS; Lin, LY, 2011) |
| "Cilostazol (CILO), a selective inhibitor of phosphodiesterase 3 with potent antithrombotic property, has been shown to have a vasculoprotective effect in atherosclerosis animal models due to its potential anti-inflammatory and antioxidant actions." | 3.76 | Vasculoprotective effect of cilostazol in aldosterone-induced hypertensive rats. ( Hirata, Y; Hirono, Y; Sakurada, M; Sekizawa, N; Suzuki, N; Yoshimoto, T, 2010) |
| "Pretreatment with cilostazol (100 mg/kg) significantly reduced infarct size." | 1.36 | Cilostazol, a phosphodiesterase inhibitor, attenuates photothrombotic focal ischemic brain injury in hypertensive rats. ( Hashimoto, A; Ito, H; Matsumoto, Y; Miyakoda, G; Yao, H, 2010) |
| "Cilostazol was then added in a cumulative manner (680-2,720 microg/L), and the tension generated was recorded." | 1.33 | Effects of cilostazol on human venous smooth muscle. ( Becker, RW; Kline, RA; Lusis, E; Sohn, RL, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 9 (56.25) | 29.6817 |
| 2010's | 6 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Reddy, SS | 1 |
| Agarwal, H | 1 |
| Barthwal, MK | 1 |
| Shinohara, Y | 1 |
| Gotoh, F | 1 |
| Tohgi, H | 1 |
| Hirai, S | 1 |
| Terashi, A | 1 |
| Fukuuchi, Y | 1 |
| Otomo, E | 1 |
| Itoh, E | 1 |
| Matsuda, T | 1 |
| Sawada, T | 1 |
| Yamaguchi, T | 1 |
| Nishimaru, K | 1 |
| Ohashi, Y | 1 |
| Ito, H | 1 |
| Hashimoto, A | 1 |
| Matsumoto, Y | 1 |
| Yao, H | 1 |
| Miyakoda, G | 1 |
| Sakurada, M | 1 |
| Yoshimoto, T | 1 |
| Sekizawa, N | 1 |
| Hirono, Y | 1 |
| Suzuki, N | 1 |
| Hirata, Y | 1 |
| Chen, JJ | 1 |
| Lee, CH | 1 |
| Lin, LY | 1 |
| Liau, CS | 1 |
| Bertelli, L | 1 |
| Amato, A | 1 |
| Sangiorgi, GM | 1 |
| Asplund, CA | 1 |
| O'Connor, FG | 1 |
| Becker, RW | 1 |
| Lusis, E | 1 |
| Sohn, RL | 1 |
| Kline, RA | 1 |
| Agrawal, NK | 1 |
| Maiti, R | 1 |
| Dash, D | 1 |
| Pandey, BL | 1 |
| Lipsitz, EC | 1 |
| Kim, S | 1 |
| Falconer, TM | 1 |
| Eikelboom, JW | 1 |
| Hankey, GJ | 1 |
| Norman, PE | 1 |
| Yang, R | 1 |
| Powell-Braxton, L | 1 |
| Ogaoawara, AK | 1 |
| Dybdal, N | 1 |
| Bunting, S | 1 |
| Ohneda, O | 1 |
| Jin, H | 1 |
| Nomura, S | 1 |
| Imamura, A | 1 |
| Okuno, M | 1 |
| Kamiyama, Y | 1 |
| Fujimura, Y | 1 |
| Ikeda, Y | 1 |
| Fukuhara, S | 1 |
| Hiatt, WR | 2 |
| Nehler, MR | 1 |
| Regensteiner, JG | 1 |
3 reviews available for cilostazol and Blood Pressure, High
| Article | Year |
|---|---|
Management of peripheral arterial disease in the elderly: focus on cilostazol.
Topics: Aged; Cilostazol; Diabetic Angiopathies; Dose-Response Relationship, Drug; Dyslipidemias; Humans; Hy | 2008 |
Peripheral arterial disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cilostazol; Diabetes Complications; Diabetes Mellitus; Dis | 2001 |
Current medical therapies for patients with peripheral arterial disease: a critical review.
Topics: Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Cardiovascular Diseases; Cilostazol; Dia | 2002 |
2 trials available for cilostazol and Blood Pressure, High
| Article | Year |
|---|---|
Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study.
Topics: Aged; Brain Ischemia; Cerebral Infarction; Cilostazol; Diabetes Complications; Double-Blind Method; | 2008 |
Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients.
Topics: Anti-Inflammatory Agents; Antioxidants; Blood Sedimentation; C-Reactive Protein; Cardiovascular Dise | 2007 |
11 other studies available for cilostazol and Blood Pressure, High
| Article | Year |
|---|---|
Cilostazol ameliorates heart failure with preserved ejection fraction and diastolic dysfunction in obese and non-obese hypertensive mice.
Topics: Angiotensin II; Animals; Biomarkers; Biopsy; Blood Pressure; Cilostazol; Diastole; Disease Models, A | 2018 |
Peripheral artery disease. Heart health for your legs.
Topics: Angioplasty, Balloon; Atherosclerosis; Cilostazol; Diabetes Complications; Exercise; Fibrinolytic Ag | 2014 |
Cilostazol, a phosphodiesterase inhibitor, attenuates photothrombotic focal ischemic brain injury in hypertensive rats.
Topics: Animals; Aspirin; Brain Ischemia; Cells, Cultured; Cerebrovascular Circulation; Cilostazol; Clopidog | 2010 |
Vasculoprotective effect of cilostazol in aldosterone-induced hypertensive rats.
Topics: Aldosterone; Animals; Aorta; Atherosclerosis; Blood Pressure; Chemokine CCL2; Cilostazol; Disease Mo | 2010 |
Determinants of lower extremity amputation or revascularization procedure in patients with peripheral artery diseases: a population-based investigation.
Topics: Aged; Amputation, Surgical; Cilostazol; Coronary Artery Disease; Female; Humans; Hypertension; Logis | 2011 |
Treatment of superficial and profunda femoral artery bifurcation lesions: still a procedure only for surgeons?
Topics: Aged; Atherosclerosis; Catheters; Chronic Disease; Cilostazol; Coronary Artery Bypass; Coronary Arte | 2012 |
An unusual cause of exertional leg pain.
Topics: Adult; Anticoagulants; Antihypertensive Agents; Cilostazol; Drug Therapy, Combination; Femoral Arter | 2004 |
Effects of cilostazol on human venous smooth muscle.
Topics: Cilostazol; Diabetes Mellitus; Dose-Response Relationship, Drug; Humans; Hypercholesterolemia; Hyper | 2005 |
Antithrombotic therapy in peripheral arterial disease.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Cilostazol; Clopidogrel; Comorbidity; Diabetic Angiopathie | 2008 |
Hypertension and endothelial dysfunction in apolipoprotein E knockout mice.
Topics: Age Factors; Animals; Apolipoproteins E; Arteriosclerosis; Cholesterol; Cilostazol; Endothelium, Vas | 1999 |
Platelet-derived microparticles in patients with arteriosclerosis obliterans: enhancement of high shear-induced microparticle generation by cytokines.
Topics: Aged; Arteriosclerosis Obliterans; Biomarkers; Blood Platelets; Blood Vessel Prosthesis Implantation | 2000 |